Lab
Holzer Hospital Foundation
Holzer Hospital Foundation was paid $121.51M by Medicaid between Jan 2018 and Dec 2024, across 503 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 61% of everything it billed.
33Billing provider infoHOLZER HOSPITAL FOUNDATION
GALLIPOLIS, OH 45631
GALLIPOLIS, OH 45631
33aNPI1942256888assigned 05/25/2006
33bProvider typeClinical Medical Laboratory
28Total paid$121.51M
24GClaims1,946,441
24DCodes billed503
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Ohio
Rank by total paid#4 of 116
Median peer was paid$313K
This provider vs. median389×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 244,361 | $10.28M | |
| 2019 | 228,833 | $9.87M | |
| 2020 | 189,160 | $13.79M | |
| 2021 | 198,759 | $15.08M | |
| 2022 | 239,041 | $19.41M | |
| 2023 | 502,548 | $29.59M | |
| 2024incomplete | 343,739 | $23.51M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 61% | 710,035 | 597,489 | $74.72M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.1% | 33,136 | 29,732 | $5.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.8% | 31,003 | 29,161 | $4.67M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.3% | 7,964 | 6,528 | $2.82M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.0% | 12,553 | 11,595 | $2.44M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 5,230 | 4,787 | $1.64M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 15,578 | 4,797 | $1.53M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 6,331 | 6,183 | $1.38M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 4,066 | 3,530 | $1.28M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,578 | 2,422 | $1.20M |
| 0240U | <1% | 5,504 | 5,124 | $1.18M | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 7,336 | 7,021 | $946K |
491 more codes
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 462 | $939K |
| 99285 | Emergency room visit (most serious) | <1% | 4,570 | $750K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,927 | $749K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,122 | $748K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,429 | $706K |
| 80053 | Comprehensive metabolic panel | <1% | 47,031 | $698K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 3,939 | $697K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,804 | $650K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,599 | $547K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 641 | $493K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,183 | $483K |
| 59025 | Fetal non-stress test | <1% | 2,588 | $457K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,203 | $432K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 508 | $404K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 90,159 | $374K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 446 | $364K |
| 20610 | <1% | 2,342 | $333K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 107,894 | $315K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 21,428 | $309K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 409 | $302K |
| 95886 | <1% | 1,304 | $265K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,686 | $262K |
| 76830 | Ultrasound, transvaginal | <1% | 1,678 | $258K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 31,806 | $254K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,583 | $240K |
| 97597 | <1% | 2,307 | $240K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,569 | $235K |
| 81003 | <1% | 14,456 | $219K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 768 | $199K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,716 | $196K |
| 64615 | <1% | 544 | $192K | |
| 80061 | Lipid panel | <1% | 15,845 | $191K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 416 | $181K |
| 95117 | <1% | 4,829 | $181K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,800 | $179K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,444 | $175K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 469 | $163K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 751 | $155K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 32,311 | $154K |
| 71271 | <1% | 635 | $148K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,134 | $146K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,917 | $138K |
| G0378 | Hospital observation service, per hour | <1% | 2,960 | $138K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12,569 | $135K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,344 | $132K |
| 62323 | <1% | 263 | $131K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 114 | $130K |
| 92557 | <1% | 1,398 | $130K | |
| 81001 | <1% | 27,621 | $127K | |
| 76536 | <1% | 859 | $126K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,057 | $124K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 22,336 | $122K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,893 | $110K |
| 47562 | <1% | 29 | $109K | |
| 76770 | <1% | 478 | $102K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 1,895 | $95K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 7,567 | $95K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 738 | $91K |
| 97161 | <1% | 1,285 | $91K | |
| 81025 | <1% | 9,349 | $88K | |
| 93017 | <1% | 619 | $88K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 26,234 | $87K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 204 | $87K |
| 76642 | <1% | 535 | $86K | |
| 86850 | <1% | 3,022 | $81K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 140 | $77K |
| 94060 | <1% | 1,566 | $74K | |
| 71250 | <1% | 951 | $72K | |
| 84484 | <1% | 16,318 | $71K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 243 | $69K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,961 | $69K |
| 73630 | <1% | 4,758 | $68K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,758 | $66K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 9,212 | $65K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,618 | $60K |
| 80076 | <1% | 13,615 | $59K | |
| 90686 | <1% | 4,131 | $57K | |
| 72110 | <1% | 1,674 | $55K | |
| 87507 | <1% | 545 | $54K | |
| 80069 | <1% | 2,287 | $54K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 27,404 | $53K |
| 93971 | <1% | 461 | $53K | |
| 85610 | <1% | 11,360 | $51K | |
| 90670 | <1% | 1,985 | $51K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 6,035 | $50K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,964 | $50K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 618 | $50K |
| 98940 | <1% | 1,718 | $49K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 461 | $49K |
| 84439 | <1% | 3,729 | $47K | |
| 70491 | <1% | 113 | $47K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 179 | $46K |
| 96367 | <1% | 466 | $46K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 713 | $46K |
| 82607 | <1% | 4,909 | $45K | |
| 82553 | <1% | 6,410 | $45K | |
| 73221 | <1% | 149 | $45K | |
| 90677 | <1% | 538 | $44K | |
| 87902 | <1% | 194 | $44K | |
| 70486 | <1% | 424 | $44K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,115 | $44K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 583 | $41K |
| 76000 | <1% | 281 | $41K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,333 | $40K |
| 90715 | <1% | 2,267 | $39K | |
| 96368 | <1% | 720 | $39K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 14 | $38K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 8,594 | $38K |
| 97162 | <1% | 578 | $38K | |
| 92133 | <1% | 892 | $37K | |
| 31575 | <1% | 179 | $37K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,531 | $37K |
| 73610 | <1% | 2,186 | $37K | |
| 92567 | <1% | 1,591 | $36K | |
| 73130 | <1% | 1,927 | $36K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,808 | $36K |
| 87340 | <1% | 2,737 | $36K | |
| 86140 | <1% | 7,317 | $35K | |
| 73562 | <1% | 2,237 | $35K | |
| 73110 | <1% | 1,372 | $34K | |
| 12001 | <1% | 154 | $34K | |
| 72050 | <1% | 887 | $34K | |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 701 | $34K |
| 93975 | <1% | 131 | $33K | |
| 80306 | <1% | 1,922 | $32K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,242 | $32K |
| 84702 | <1% | 1,610 | $32K | |
| 86780 | <1% | 2,364 | $32K | |
| 87522 | Neg quan hep c or qual rna | <1% | 951 | $32K |
| 94729 | <1% | 1,458 | $31K | |
| 94726 | <1% | 1,459 | $31K | |
| 86803 | <1% | 2,681 | $31K | |
| 87420 | <1% | 1,410 | $28K | |
| 82550 | <1% | 7,088 | $27K | |
| 17110 | <1% | 339 | $27K | |
| 85730 | <1% | 8,489 | $27K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,448 | $26K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,047 | $26K |
| 43235 | <1% | 57 | $25K | |
| 72131 | <1% | 177 | $25K | |
| 82746 | <1% | 4,416 | $25K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,010 | $25K |
| 83655 | <1% | 1,251 | $25K | |
| 93458 | <1% | 15 | $25K | |
| 88304 | <1% | 607 | $25K | |
| 96127 | <1% | 272 | $25K | |
| 93242 | <1% | 442 | $25K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,125 | $23K |
| 73030 | <1% | 1,750 | $23K | |
| 82570 | <1% | 3,056 | $23K | |
| 74018 | <1% | 1,637 | $22K | |
| 86900 | <1% | 1,351 | $22K | |
| 77080 | <1% | 228 | $21K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,849 | $21K |
| 80320 | <1% | 1,330 | $21K | |
| 89190 | <1% | 2,466 | $21K | |
| 82728 | <1% | 1,831 | $20K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 610 | $20K |
| 70498 | <1% | 81 | $20K | |
| 10060 | <1% | 95 | $19K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,971 | $19K |
| 74178 | <1% | 52 | $18K | |
| 83540 | <1% | 2,811 | $18K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,144 | $17K |
| 83605 | <1% | 5,251 | $17K | |
| 86709 | <1% | 978 | $17K | |
| 11981 | <1% | 57 | $17K | |
| 86480 | <1% | 367 | $16K | |
| 76882 | <1% | 119 | $16K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,245 | $16K |
| 83690 | <1% | 9,403 | $16K | |
| 83735 | <1% | 3,992 | $16K | |
| 83550 | <1% | 2,589 | $15K | |
| 84156 | <1% | 1,888 | $15K | |
| 77066 | Tomosynthesis, mammo | <1% | 260 | $15K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 241 | $15K |
| J0558 | Injection, penicillin g benzathine and penicillin g procaine, 100,000 units | <1% | 67 | $14K |
| 72072 | <1% | 596 | $14K | |
| 73502 | <1% | 837 | $14K | |
| 82947 | <1% | 2,622 | $14K | |
| 86706 | <1% | 1,164 | $14K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 58 | $14K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 53 | $14K |
| 83970 | <1% | 531 | $14K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,709 | $14K |
| 86762 | <1% | 828 | $13K | |
| 90648 | <1% | 2,904 | $13K | |
| 97598 | <1% | 49 | $13K | |
| 70496 | <1% | 82 | $13K | |
| 86376 | <1% | 964 | $13K | |
| 97166 | <1% | 168 | $13K | |
| 20605 | <1% | 62 | $13K | |
| 87186 | <1% | 4,085 | $12K | |
| 87070 | <1% | 1,949 | $12K | |
| J3490 | Unclassified drugs | <1% | 1,969 | $12K |
| 87077 | <1% | 4,149 | $12K | |
| 81596 | <1% | 61 | $12K | |
| 92587 | <1% | 127 | $12K | |
| 90723 | <1% | 2,082 | $11K | |
| 51798 | <1% | 548 | $11K | |
| 85018 | <1% | 2,365 | $11K | |
| 90633 | <1% | 1,735 | $11K | |
| 90651 | <1% | 1,151 | $11K | |
| 73080 | <1% | 683 | $11K | |
| 87210 | <1% | 1,018 | $11K | |
| 90837 | Psychotherapy session, about an hour | <1% | 61 | $11K |
| 74019 | <1% | 634 | $10K | |
| 86705 | <1% | 710 | $10K | |
| 86704 | <1% | 613 | $10K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 32 | $10K |
| G0008 | Administration of influenza virus vaccine | <1% | 4,569 | $10K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 531 | $10K |
| 99174 | <1% | 186 | $10K | |
| 86038 | <1% | 1,056 | $10K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 374 | $10K |
| 82247 | <1% | 579 | $10K | |
| 90734 | <1% | 1,210 | $9K | |
| 92134 | <1% | 333 | $9K | |
| 86003 | <1% | 1,306 | $9K | |
| 31237 | <1% | 20 | $9K | |
| 93296 | <1% | 639 | $9K | |
| 85652 | <1% | 3,258 | $9K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,871 | $9K |
| 31231 | <1% | 46 | $9K | |
| 84112 | <1% | 107 | $9K | |
| 93880 | <1% | 73 | $8K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,254 | $8K |
| 82962 | <1% | 3,864 | $8K | |
| 64493 | <1% | 34 | $8K | |
| 95811 | <1% | 24 | $8K | |
| 11750 | <1% | 69 | $8K | |
| 86364 | <1% | 1,149 | $8K | |
| 86901 | <1% | 1,351 | $8K | |
| 82784 | <1% | 1,343 | $7K | |
| 73590 | <1% | 463 | $7K | |
| 82043 | <1% | 1,188 | $7K | |
| 82785 | <1% | 874 | $7K | |
| 99152 | <1% | 361 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,092 | $7K |
| 84436 | <1% | 757 | $7K | |
| 84100 | <1% | 823 | $7K | |
| 84403 | <1% | 520 | $7K | |
| 74183 | <1% | 27 | $7K | |
| 82248 | <1% | 706 | $6K | |
| 94010 | <1% | 1,518 | $6K | |
| 80361 | <1% | 568 | $6K | |
| 90656 | <1% | 555 | $6K | |
| 73140 | <1% | 391 | $6K | |
| 86430 | <1% | 946 | $6K | |
| 11982 | <1% | 34 | $6K | |
| 84153 | <1% | 416 | $6K | |
| 83880 | <1% | 1,770 | $6K | |
| 71101 | <1% | 322 | $5K | |
| 80346 | <1% | 457 | $5K | |
| 84402 | <1% | 325 | $5K | |
| G0127 | Trimming of dystrophic nails, any number | <1% | 317 | $5K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,023 | $5K |
| 80324 | <1% | 488 | $5K | |
| 86258 | <1% | 801 | $5K | |
| 87150 | <1% | 485 | $5K | |
| 90716 | <1% | 548 | $5K | |
| 90696 | <1% | 755 | $5K | |
| 83001 | <1% | 394 | $5K | |
| 87040 | <1% | 2,956 | $4K | |
| 90710 | <1% | 862 | $4K | |
| 86757 | <1% | 1,308 | $4K | |
| 84479 | <1% | 654 | $4K | |
| 84550 | <1% | 1,149 | $4K | |
| 86618 | <1% | 767 | $4K | |
| H1003 | Prenatal care, at-risk enhanced service; education | <1% | 197 | $4K |
| 82565 | <1% | 722 | $4K | |
| 84481 | <1% | 397 | $4K | |
| 83992 | <1% | 275 | $4K | |
| 84270 | <1% | 313 | $4K | |
| 73090 | <1% | 372 | $4K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 13 | $4K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 470 | $4K |
| 80365 | <1% | 433 | $4K | |
| 86231 | <1% | 408 | $4K | |
| 90700 | <1% | 610 | $4K | |
| 96376 | <1% | 1,289 | $4K | |
| 84146 | <1% | 267 | $4K | |
| 99406 | <1% | 193 | $4K | |
| 95912 | <1% | 69 | $4K | |
| 90662 | <1% | 304 | $4K | |
| 80348 | <1% | 535 | $4K | |
| 90707 | <1% | 571 | $3K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,607 | $3K |
| 86235 | <1% | 385 | $3K | |
| 83993 | <1% | 121 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 486 | $3K |
| 77002 | <1% | 16 | $3K | |
| 86666 | <1% | 700 | $3K | |
| 93970 | <1% | 15 | $3K | |
| 80350 | <1% | 275 | $3K | |
| 73560 | <1% | 176 | $3K | |
| 20550 | <1% | 16 | $3K | |
| 73564 | <1% | 151 | $3K | |
| 12002 | <1% | 12 | $3K | |
| 11721 | <1% | 215 | $3K | |
| 74022 | <1% | 221 | $3K | |
| 82274 | <1% | 151 | $3K | |
| 90681 | <1% | 983 | $3K | |
| 86580 | <1% | 98 | $3K | |
| 83615 | <1% | 758 | $3K | |
| 80356 | <1% | 357 | $3K | |
| 94664 | <1% | 925 | $3K | |
| 86008 | <1% | 428 | $3K | |
| 80349 | <1% | 322 | $3K | |
| 80354 | <1% | 349 | $3K | |
| 80353 | <1% | 414 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,469 | $2K |
| 95909 | <1% | 63 | $2K | |
| 86317 | <1% | 143 | $2K | |
| 93922 | <1% | 15 | $2K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 356 | $2K |
| 82040 | <1% | 313 | $2K | |
| 93270 | <1% | 26 | $2K | |
| 84703 | <1% | 661 | $2K | |
| 72100 | <1% | 36 | $2K | |
| 83721 | <1% | 248 | $2K | |
| 85379 | <1% | 1,703 | $2K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 13 | $2K |
| 80373 | <1% | 275 | $2K | |
| 82105 | <1% | 419 | $2K | |
| 85384 | <1% | 604 | $2K | |
| 00840 | <1% | 188 | $2K | |
| 64450 | <1% | 14 | $2K | |
| 85014 | <1% | 856 | $2K | |
| 81000 | <1% | 320 | $2K | |
| 82150 | <1% | 2,335 | $2K | |
| 86200 | <1% | 199 | $2K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 940 | $2K |
| 97116 | <1% | 42 | $2K | |
| 00731 | <1% | 1,041 | $2K | |
| 73552 | <1% | 118 | $2K | |
| 85027 | <1% | 511 | $2K | |
| 86225 | <1% | 208 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,503 | $2K |
| 84165 | <1% | 301 | $2K | |
| 86696 | <1% | 323 | $2K | |
| 84460 | <1% | 436 | $1K | |
| 86695 | <1% | 307 | $1K | |
| 86665 | <1% | 219 | $1K | |
| 86708 | <1% | 134 | $1K | |
| 84450 | <1% | 393 | $1K | |
| 86308 | <1% | 401 | $1K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,734 | $1K |
| 80360 | <1% | 143 | $1K | |
| 80355 | <1% | 263 | $1K | |
| 80358 | <1% | 275 | $1K | |
| 73060 | <1% | 63 | $1K | |
| 96523 | <1% | 33 | $1K | |
| 82670 | <1% | 96 | $1K | |
| 92083 | <1% | 42 | $1K | |
| 76870 | <1% | 70 | $1K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 412 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 7,485 | $1K |
| 80164 | <1% | 47 | $1K | |
| 86753 | <1% | 283 | $1K | |
| 82977 | <1% | 126 | $1K | |
| 82731 | <1% | 15 | $977.75 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 731 | $944.20 |
| 76820 | <1% | 56 | $923.98 | |
| 85007 | <1% | 488 | $880.21 | |
| 73521 | <1% | 35 | $850.29 | |
| 80362 | <1% | 88 | $828.88 | |
| 86160 | <1% | 74 | $805.67 | |
| 82140 | <1% | 184 | $801.23 | |
| 84145 | <1% | 348 | $749.05 | |
| 82803 | <1% | 798 | $748.13 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,928 | $726.10 |
| 90732 | <1% | 24 | $709.91 | |
| 80047 | <1% | 150 | $679.15 | |
| 95024 | <1% | 327 | $656.87 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 480 | $636.91 |
| 82533 | <1% | 16 | $623.60 | |
| 29125 | <1% | 181 | $620.29 | |
| 88342 | <1% | 1,607 | $617.19 | |
| 86664 | <1% | 113 | $604.80 | |
| 69210 | <1% | 233 | $595.29 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,766 | $588.76 |
| 80329 | <1% | 396 | $571.02 | |
| 00126 | <1% | 237 | $566.97 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,203 | $542.14 |
| 84207 | <1% | 102 | $497.90 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 218 | $480.61 |
| 77065 | Tomosynthesis, mammo | <1% | 12 | $478.55 |
| 00813 | <1% | 1,072 | $478.50 | |
| 83520 | <1% | 39 | $467.20 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,767 | $461.01 |
| 87641 | <1% | 37 | $460.15 | |
| 11055 | <1% | 14 | $452.08 | |
| 36600 | <1% | 165 | $447.90 | |
| 72081 | <1% | 14 | $433.37 | |
| 87205 | <1% | 486 | $432.09 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 4,724 | $427.70 |
| 87338 | <1% | 12 | $364.76 | |
| 84520 | <1% | 89 | $358.56 | |
| 69209 | <1% | 411 | $358.33 | |
| 86677 | <1% | 60 | $354.77 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,328 | $349.48 |
| 86738 | <1% | 13 | $334.36 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 4,145 | $325.26 |
| 86703 | <1% | 41 | $281.75 | |
| J1815 | Injection, insulin, per 5 units | <1% | 124 | $272.58 |
| 84480 | <1% | 12 | $271.27 | |
| 80345 | <1% | 15 | $265.66 | |
| 90620 | <1% | 51 | $251.78 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 17 | $247.74 |
| 86334 | <1% | 15 | $240.58 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,377 | $220.54 |
| 92504 | <1% | 1,328 | $218.15 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 494 | $213.18 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 198 | $208.60 |
| 83002 | <1% | 14 | $207.38 | |
| 36416 | <1% | 358 | $201.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 197 | $200.10 |
| 84425 | <1% | 24 | $199.15 | |
| 82375 | <1% | 178 | $185.58 | |
| 85045 | <1% | 57 | $182.89 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,173 | $161.32 |
| 01992 | <1% | 299 | $151.28 | |
| 90381 | <1% | 14 | $143.80 | |
| 88341 | <1% | 17 | $142.92 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,797 | $132.37 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 1,296 | $118.28 |
| 73565 | <1% | 33 | $115.82 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 476 | $96.77 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 399 | $92.75 |
| 83090 | <1% | 12 | $91.84 | |
| 92136 | <1% | 12 | $91.31 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 111 | $90.59 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 259 | $88.05 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,048 | $71.39 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 881 | $60.33 |
| 82103 | <1% | 13 | $52.03 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 294 | $44.37 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,127 | $43.06 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 459 | $39.28 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 940 | $39.10 |
| 86774 | <1% | 13 | $38.60 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 761 | $32.13 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 446 | $30.96 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 469 | $29.72 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 790 | $28.45 |
| G0379 | Direct admission of patient for hospital observation care | <1% | 332 | $20.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 22 | $19.14 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 494 | $11.88 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 346 | $11.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 38 | $7.19 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 566 | $6.65 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 81 | $6.42 |
| 94760 | <1% | 527 | $4.55 | |
| 91320 | <1% | 27 | $4.34 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 44 | $4.02 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 181 | $3.48 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 149 | $2.96 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 94 | $2.70 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 19 | $1.16 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 98 | $1.13 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 210 | $0.64 |
| 91300 | <1% | 20 | $0.15 | |
| C1773 | Retrieval device, insertable (used to retrieve fractured medical devices) | 0% | 199 | $0.00 |
| A9270 | Non-covered item or service | 0% | 793 | $0.00 |
| 00142 | 0% | 41 | $0.00 | |
| 90480 | 0% | 70 | $0.00 | |
| 01480 | 0% | 18 | $0.00 | |
| C1769 | Guide wire | 0% | 633 | $0.00 |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | 0% | 162 | $0.00 |
| C1766 | Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away | 0% | 174 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 229 | $0.00 |
| 95012 | 0% | 25 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 54 | $0.00 |
| 00790 | 0% | 37 | $0.00 | |
| 00952 | 0% | 19 | $0.00 | |
| Q9960 | High osmolar contrast material, 200-249 mg/ml iodine concentration, per ml | 0% | 474 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 270 | $0.00 |
| 00812 | 0% | 72 | $0.00 | |
| 00811 | 0% | 453 | $0.00 | |
| 80305 | 0% | 30 | $0.00 | |
| 90671 | 0% | 662 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 214 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 296 | $0.00 |
| 01810 | 0% | 90 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 87 | $0.00 |
| H1000 | Prenatal care, at-risk assessment | 0% | 197 | $0.00 |
| 92015 | Determination of refractive state | 0% | 53 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 14 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 13 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTOUT, RODNEY (CEO)
| Provider | Location | Paid |
|---|---|---|
| Holzer Hospital Foundation | Gallipolis, OH | $1.04M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.